Corcept Therapeutics | CORT - Net Income


Corcept Therapeutics reported $24.29M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 273.57M 201.79M Dec/2025
Alaunos Therapeutics USD -1.16M 108K Sep/2025
ANI Pharmaceuticals USD 32.35M 6.08M Dec/2025
Ardelyx USD -407K 562K Dec/2025
Assertio Holdings USD -2.92M 753K Sep/2024
Aurora Cannabis CAD 1.82M 53.29M Dec/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Canopy Growth CAD -62.63M 60.99M Dec/2025
Corcept Therapeutics USD 24.29M 4.62M Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
J&J USD 5.12B 36M Dec/2025
Knight Therapeutics CAD -3.79M 8.83M Sep/2025
Lexicon Pharmaceuticals USD -15.53M 2.76M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 1.64M 3.8M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Supernus Pharmaceuticals USD -45.12M 67.62M Sep/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025